Quote | Senti Biosciences Inc. (NASDAQ:SNTI)
Last: | $0.375 |
---|---|
Change Percent: | -2.09% |
Open: | $0.39 |
Close: | $0.375 |
High: | $0.39 |
Low: | $0.37 |
Volume: | 19,988 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
News | Senti Biosciences Inc. (NASDAQ:SNTI)
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
2024-05-10 07:46:46 ET More on Senti Biosciences Financial information for Senti Biosciences Read the full article on Seeking Alpha For further details see: Senti Biosciences GAAP EPS of -$0.26
Message Board Posts | Senti Biosciences Inc. (NASDAQ:SNTI)
Subject | By | Source | When |
---|---|---|---|
lets see 2.0 next step???? | konshe | investorshub | 10/20/2022 6:11:13 PM |
znewcar1: SNTI 23% v47,9M c6.52 f43,7M H8.77 ML1.2 | znewcar1 | investorshangout | 10/07/2022 3:51:36 AM |
$SNTI: Bottom line, Z-G, ain't we BOTH happy | Invest-in-America | investorshub | 10/06/2022 2:40:31 PM |
Thanks!.....Makes it a lot easier to pick out | Zardiw | investorshub | 10/05/2022 12:38:30 PM |
NICE!!! I LOVE those COLORS!!! | Invest-in-America | investorshub | 10/05/2022 12:21:25 AM |
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter ...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...